'Winning in Business in Spain' Award

RNS Number : 6773D

Oncimmune Holdings PLC

21 February 2020

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Oncimmune receives 'Winning in Business in Spain' award for distribution of EarlyCDT ^® Lung in Spain

21 February 2020 - Oncimmune Holdings plc (AIM: ONC.L), a leading global immunodiagnostics group, is pleased to announce it has been awarded the 'Winning in Business in Spain' award at the Department for International Trade's (DIT) UK-Spain Business Awards held on 20th February 2020 at the Madrid Stock Exchange in Spain.

These awards celebrate the extensive commercial relationships between the United Kingdom and Spain.

The DIT's introduction of Sabartech has enabled Oncimmune to build its successful distribution partnership with Sabartech, which has led to making EarlyCDT Lung available in Spain and Portugal.

Javier Sarasqueta, Co-founder and CEO of Sabartech said "Sabartech and Oncimmune have developed a great partnership that has helped launch EarlyCDT Lung in the Spanish market. We are looking forward to building on this to improve the early detection of lung cancer in both the private and public healthcare systems. This award is a fantastic recognition of all we have achieved so far."

Dr Adam M Hill, CEO of Oncimmune said: " This award is testament to the strong relationship we have fostered with Sabartech. Every year there are 23,000 lung cancer deaths in Spain¹. The key to improving lung cancer survival is early detection and we are delighted that our EarlyCDT Lung test is continuing to gain momentum in screening in Spain and beating cancer, one test at a time."

^[1]   GLOBOCAN 2018 (WHO)

-Ends-

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

[phone]

finnCap (Joint Broker)

Geoff Nash, Matthew Radley, Tim Redfern

[phone]

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

[phone]

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[e-mail]

[phone]

About Oncimmune

Beating cancer, one test at a time

The battle against cancer hinges on early detection and then the delivery of effective treatment. Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 160,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS trial of 12,209 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

What is EarlyCDT Lung?

A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.

For more information, visit www.oncimmune.com

 

END

 

 

NRADBGDDRDDDGGG